Clinical trials: Neoplastic Cells, Circulating
Healthy Volunteers, Breast Cancer, Metastatic
Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System
The purpose of this clinical study is to demonstrate that the Parsortix™ PC1 system enables the capture and harvest of circulating tumor cells (CTCs) from the peripheral blood of patients with metastatic breast cancer (MBC) and…
- Trial name
- HOMING (NCT03427450)
- Testing
- Blood draw
- Where
- 4 sites in United States
- Volunteers
- 421 people, healthy volunteers welcome
- Sponsor
- Angle plc
Prostate Cancer
Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
Primary Objective: To assess effectiveness of prophylactic treatment of hematological complications (grade ≥ 3 neutropenia) resulting from cabazitaxel treatment for 21 days after treatment initiation.
- Trial name
- PROSPECTA (NCT01649635)
- Testing
- CABAZITAXEL (XRP6258), Prednisone, Ciprofloxacin
- Where
- 6 sites in Brazil
- Volunteers
- 45 people
- Sponsor
- Sanofi
Solid Tumor, Adult, Healthy Donors
A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.
Primary Objective: This is a study to investigate the feasibility of harvesting, expanding, and selecting T lymphocytes from cancer patients and healthy volunteers.
- Conditions
- Solid Tumor, Adult, Healthy Donors, COVID-19 Donors
- Trial name
- NCT00571389
- Where
- United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- BioCytics, Inc.
Metastatic Breast Cancer
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
Utilizing CellSearch® technology, the ability to both enumerate and reliably and reproducibly characterize circulating tumor cells (CTC) for tumor markers that predict endocrine sensitivity (estrogen receptor [ER] and Bcl-2) and…
- Trial name
- COMETI P2 (NCT01701050)
- Testing
- Blood collection
- Where
- 20 sites in United States, Canada
- Volunteers
- 121 people
- Sponsor
- Janssen Diagnostics, LLC
Prostate Cancer
Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)
The main objective of this study is to evaluate the effects of PLX3397 on male subjects with CRPC. Secondary objectives include evaluating the safety and tolerability of PLX3397 and the anti-tumor effects that PLX3397 has on the…
- Trial name
- NCT01499043
- Testing
- PLX3397
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Daiichi Sankyo
Cancer, Solid Tumor
MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment
This study recruits patient with solid tumor types for sample collection and monitoring. Participants will provide blood and archival tissue samples in order to create a Personalized Cancer Monitoring (PCM) assay.
- Conditions
- Cancer, Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- MARIA (NCT05219734)
- Testing
- Personalized Cancer Monitoring (PCM)
- Where
- 2 sites in United States
- Volunteers
- 400 people
- Sponsor
- Invitae Corporation
Prostate Cancer
Assessing Circulating Tumor Cell as a Biomarker for Prostate Cancer Detection in Patients With Gray Zone PSA Level
Prostate cancer screening with PSA is plagued by high rate of unnecessary prostate biopsies, especially in the "gray zone" (4.00ng/ml e 10.99ng/ml).
- Trial name
- NCT03488706
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- CellMaxLife
Breast Cancer, Prostate Cancer
Collection of Blood Specimens for Circulating Tumor Cell Analysis
Objective: To test the sensitivity of a proprietary novel filtration device designed to capture and concentrate circulating tumor cells (CTCs).
- Conditions
- Breast Cancer, Prostate Cancer, Colorectal Cancer
- Trial name
- NCT01943500
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Viatar LLC
Circulating Tumor Cells, CTC
CTCs and Novel Target Bio-marker Analysis for Prediction and Monitoring of Metastasis/Recurrence in Post-surgery Colorectal Cancer Patients Using MiSelect R Rare Cell System
Despite the growing public awareness and recent progress in multimodality therapy to the colorectal cancer (CRC), CRC still ranks high on the list of the most common and deadly cancers in Taiwan.
- Trial name
- NCT03013868
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- MiCareo Taiwan Co., Ltd.
Melanoma, Circulating Tumor Cells
In Vivo Liquid Biopsy of Melanoma (Cytophone)
The Cytophone is a first in the world patented system to identify and count single circulating melanoma cells in blood circulation inside the human body.
- Conditions
- Melanoma, Circulating Tumor Cells, Metastatic Melanoma, Diagnosis
- Trial name
- Cytophone (NCT06488365)
- Testing
- Cytophone
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Cytoastra
Ovarian Neoplasms
Evaluation of Multiple Biomarkers to Estimate Risk of Ovarian Cancer in Patients With a Pelvic Mass.
ANGLE has developed the Parsortix™ Cell Separation System (Parsortix), an automated system capable of harvesting rare circulating cells for analysis from a sample of peripheral blood based on cellular size and deformability.
- Trial name
- NCT02785731
- Testing
- Pelvic imaging, Blood draw, laparotomy or laparoscopy
- Where
- 5 sites in Austria, Germany
- Volunteers
- 204 people
- Sponsor
- Angle plc
Colo-rectal Cancer
Clinical Application of an Automated Liquid Biopsy Platform for Early Detection of Colorectal Cancer
Colorectal cancer (CRC) is among the most preventable cancers when precancerous lesions are detected at an early stage. Current screening methods for CRC require bowel prep or stool-based testing that are inconvenient, resulting…
- Trial name
- NCT03476122
- Where
- Taiwan
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- CellMaxLife
Metastatic Breast Cancer, Breast Cancer
Clinical Utility of CTC Test in Medicare-Eligible Metastatic Breast Cancer Patients
The objective of the registry study is to demonstrate the clinical utility of the CELLSEARCH® CTC Test among the Medicare-Eligible metastatic Breast Cancer (mBC) patients in the United States.
- Trial name
- NCT02111031
- Where
- 2 sites in United States
- Sponsor
- Janssen Diagnostics, LLC
Non-small-cell Lung Carcinoma
The Value Of Circulating Tumor Cells In Patient With NSCLC In Postoperative Recurrence Monitoring
The purpose of this study is to assess the value of circulating tumor cells (CTC)for non-small cell lung cancer in the postoperative recurrence monitoring by comparing the CTCs, CT and tumor markers at different time points.The…
- Trial name
- NCT02647164
- Volunteers
- 360 people
- Sponsor
- GenoSaber
Metastatic Breast Cancer
ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)
ACT-MBC prospectively assesses the impact of CTCs on treatment decisions, response assessment and prognosis in MBC patients.
- Trial name
- ACT-MBC (NCT05662345)
- Testing
- CellSearch Circulating Tumor Cells
- Where
- 4 sites in United States
- Volunteers
- 65 people
- Sponsor
- Menarini Silicon Biosystems, INC
CTC and Tumor Related Rare Cell
Identification and Evaluation of Circulating Tumor Cells and Tumor Related Rare Cells in Immunotherapy
The primary objective of this study is designed to evaluate the enumeration of circulating tumor cells and identify the potential biomarkers associated with clinical outcome.
- Trial name
- NCT03434912
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- MiCareo Taiwan Co., Ltd.
Hormone Refractory Prostate Cancer, Prostate Cancer
Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemotherapy
This study enrolled men with prostate cancer who had failed hormone therapy (as shown by rising prostate-specific antigen [PSA] levels) and who were about to start a new line of chemotherapy.
- Trial name
- IMMC-38 (NCT00133900)
- Testing
- Phlebotomy
- Where
- United States
- Volunteers
- 276 people
- Sponsor
- Immunicon
Metastatic Cancer
Evaluation of Viatar™ Oncopheresis System in Removing CTC From Whole Blood
This study will access the safety and efficacy of the Viatar™ Oncopheresis System to remove a meaningful quantity of circulating tumor cells from the blood of subjects' with breast, colon or prostate solid tumor cancers in a…
- Trial name
- NCT03058809
- Testing
- Oncopheresis
- Volunteers
- 100 people
- Sponsor
- Viatar LLC
Circulating Tumor Cells (CTCs)
Detection of Circulating Tumor Cells in Peripheral Blood From Healthy Volunteers and Patients With Cancer
To address the challenges of isolating and analyzing rare cells, this study aims to validate technical diagnostic instrumentation, tests, protocols and analysis to correlate the number of circulating tumor cells present in whole…
- Trial name
- NCT02904161
- Where
- Taiwan
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- MiCareo Taiwan Co., Ltd.